Generic manufacturers seeking to put an end to Hatch-Waxman Act patent litigation over a branded company’s Orange Book-listed patents can seek to do so by converting from Paragraph IV (“PIV”) patent certifications to...more
7/14/2020
/ Abbreviated New Drug Application (ANDA) ,
Article III ,
Case or Controversy ,
Certifications ,
Dismissals ,
FDA Approval ,
Generic Drugs ,
Hatch-Waxman ,
Judgment on the Pleadings ,
Orange Book ,
Patent Infringement ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Ripeness ,
Sandoz ,
Subject Matter Jurisdiction